Adicet Bio, Inc. (ACET) stock
ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
$2.75−0.03 (-1.08%)
Close on Nov 16, 2026Market cap $25.74MP/E –Yield –
Adicet Bio total assets
Total assets on the balance sheet at the end of each period.
Adicet Bio's total assets was $148.17M at Jun 30, 2026. For fiscal 2025 it was $192.36M, down 12.7% from the year before. The highest annual figure on record is $338.94M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $192.36M | -12.7% |
| FY2024 | Dec 31, 2024 | $220.22M | +6.2% |
| FY2023 | Dec 31, 2023 | $207.30M | -37.3% |
| FY2022 | Dec 31, 2022 | $330.69M | -2.4% |
| FY2021 | Dec 31, 2021 | $338.94M | +120.3% |
| FY2020 | Dec 31, 2020 | $153.84M | +88.6% |
| FY2019 | Dec 31, 2019 | $81.59M | -25.8% |
| FY2018 | Dec 31, 2018 | $109.94M | +99.2% |
| FY2017 | Dec 31, 2017 | $55.19M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $148.17M | -9.1% |
| Q1 FY2026 | Mar 31, 2026 | $169.38M | -11.4% |
| Q4 FY2025 | Dec 31, 2025 | $192.36M | -12.7% |
| Q3 FY2025 | Sep 30, 2025 | $140.48M | -42.9% |
| Q2 FY2025 | Jun 30, 2025 | $162.97M | -39.4% |
| Q1 FY2025 | Mar 31, 2025 | $191.27M | -34.7% |
| Q4 FY2024 | Dec 31, 2024 | $220.22M | +6.2% |
| Q3 FY2024 | Sep 30, 2024 | $245.96M | +5.4% |
| Q2 FY2024 | Jun 30, 2024 | $268.84M | -3.2% |
| Q1 FY2024 | Mar 31, 2024 | $293.10M | -3.9% |
| Q4 FY2023 | Dec 31, 2023 | $207.30M | -37.3% |
| Q3 FY2023 | Sep 30, 2023 | $233.26M | -34.2% |
| Q2 FY2023 | Jun 30, 2023 | $277.63M | -15.8% |
| Q1 FY2023 | Mar 31, 2023 | $304.97M | -10.4% |
| Q4 FY2022 | Dec 31, 2022 | $330.69M | -2.4% |
| Q3 FY2022 | Sep 30, 2022 | $354.30M | +37.8% |
| Q2 FY2022 | Jun 30, 2022 | $329.90M | +22.7% |
| Q1 FY2022 | Mar 31, 2022 | $340.45M | +20.7% |
| Q4 FY2021 | Dec 31, 2021 | $338.94M | +120.3% |
| Q3 FY2021 | Sep 30, 2021 | $257.20M | +71.0% |
| Q2 FY2021 | Jun 30, 2021 | $268.78M | +261.5% |
| Q1 FY2021 | Mar 31, 2021 | $282.07M | +260.7% |
| Q4 FY2020 | Dec 31, 2020 | $153.84M | +88.6% |
| Q3 FY2020 | Sep 30, 2020 | $150.40M | +23.3% |
| Q2 FY2020 | Jun 30, 2020 | $74.34M | -45.6% |
| Q1 FY2020 | Mar 31, 2020 | $78.21M | -46.1% |
| Q4 FY2019 | Dec 31, 2019 | $81.59M | -25.8% |
| Q3 FY2019 | Sep 30, 2019 | $121.96M | +3.9% |
| Q2 FY2019 | Jun 30, 2019 | $136.66M | +6.1% |
| Q1 FY2019 | Mar 31, 2019 | $145.08M | +5.7% |
| Q4 FY2018 | Dec 31, 2018 | $109.94M | +99.2% |
| Q3 FY2018 | Sep 30, 2018 | $117.43M | – |
| Q2 FY2018 | Jun 30, 2018 | $128.78M | – |
| Q1 FY2018 | Mar 31, 2018 | $137.25M | – |
| Q4 FY2017 | Dec 31, 2017 | $55.19M | – |
See a number that looks wrong?